Literature DB >> 16388093

A RET mutation with decreased penetrance in the family of a patient with a "sporadic" pheochromocytoma.

Seth M Arum1, Patricia L M Dahia, Katherine Schneider, Lewis E Braverman.   

Abstract

We present the case of a 38-yr-old man with a sporadic, multifocal pheochromocytoma and paraganglioma who was discovered to carry a Y791F germline mutation in exon 13 of the RET proto-oncogene. This mutation was found in his 65-yr-old mother and his 86-yr-old maternal grandmother. Neither of them had either biochemical evidence of pheochromocytoma or medullary thyroid carcinoma. The patient had a pro-phylactic thyroidectomy, which revealed mild C-cell hyperplasia. This case brings to discussion several issues: (1) the benefit of screening patients with apparently sporadic pheochromocytomas for genetic mutations; (2) the management of patients and families with "lower-risk" RET mutations; and (3) the possibility that lower-penetrance RET mutations may contribute to the list of causes of familial pheochromocytomas.

Entities:  

Mesh:

Year:  2005        PMID: 16388093     DOI: 10.1385/ENDO:28:2:193

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  23 in total

1.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

2.  Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.

Authors:  Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas.

Authors:  R C Aguiar; G Cox; S L Pomeroy; P L Dahia
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

5.  A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.

Authors:  I Berndt; M Reuter; B Saller; K Frank-Raue; P Groth; M Grussendorf; F Raue; M M Ritter; W Höppner
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

6.  Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin.

Authors:  H Vierhapper; C Bieglmayer; G Heinze; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2004-08       Impact factor: 6.568

7.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

8.  RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?

Authors:  Oliver Gimm; Barbara E Niederle; Theresa Weber; Maximilian Bockhorn; Jörg Ukkat; Michael Brauckhoff; Phuong Nguyen Thanh; Andreja Frilling; Ernst Klar; Bruno Niederle; Henning Dralle
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

9.  Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma.

Authors:  P A Crossey; C Eng; M Ginalska-Malinowska; T W Lennard; D C Wheeler; B A Ponder; E R Maher
Journal:  J Med Genet       Date:  1995-11       Impact factor: 6.318

10.  Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland.

Authors:  S A Wells; S B Baylin; W M Linehan; R E Farrell; E B Cox; C W Cooper
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

View more
  3 in total

1.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

2.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

3.  Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.

Authors:  F O F Valente; M R Dias da Silva; C P Camacho; I S Kunii; A U Bastos; C C N da Fonseca; H P C Simião; R Tamanaha; R M B Maciel; J M Cerutti
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.